USACIG signs exclusive agreement with Hop-on for prevention of Parkinson's disease

USACIG, Inc. and Hop-on, Inc. (PINKSHEETS: HPNN) are proud to announce that USACIG has signed an exclusive agreement with Hop-on, Inc. to submit its Electric Cigarette Nicotine water technology to the FDA for clinical studies for the prevention of Parkinson's disease and for the alleviation of its symptoms.

Peter Michaels, CEO of Hop-on, states, "Studies on nicotine through cigarette use have proven to delay the onset of Parkinson's disease. Nicotine in its natural state removed from cigarettes is safe and non-toxic. USACIG nicotine water technology delivers pure organic and non-toxic nicotine without harmful chemicals. While nicotine has had an image problem due to its association with smoking, there is much excitement about nicotine's potential to prevent and help with a number of medical issues. We are very excited about being USACIG's exclusive agent for FDA submission. USACIG will be working on the funding for clinical studies."

The Parkinson's Institute and Clinical Center is also continuing research showing that intermittent nicotine treatment reduces medication-induced dyskinesias by as much as 50% in models of Parkinson's disease. Lead by senior research scientist, Maryka Quik, Ph.D.